Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR T Cells with Safety Switch for B Cell Malignancies
NCT02456350Phase 1Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Apr 2015
- Primary completion
- Dec 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mivocabtagene autoleucel in B-cell leukemia (BCL) and B cell lymphoma, sponsored by Shenzhen Second People's Hospital. Primary endpoint: Number of participants with Adverse Events at 8 weeks. Status: unknown.
02
Drugs
mivocabtagene autoleucel
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT02456350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02456350.